$KEQU

HULL THOMAS DAVID III sold (to issuer) $616K of KEQU

HULL THOMAS DAVID III (President & CEO) sold (to issuer) 17,000 shares of KEWAUNEE SCIENTIFIC CORP /DE/ (KEQU) at $36.25 ($0.62M total) on 2026-06-30.

Original reporting
SEC EDGAR · HULL THOMAS DAVID III
Published Jul 2, 2026, 3:47 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jul 2, 2026, 3:51 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$KEQU
Neutral
medium confidence
Mentioned
$KEQU
Relevance
5/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$KEQUNeutralLow
01

Why it matters

The newest fact is the CEO’s sale of 17,000 shares at $36.25 to the issuer on 2026-06-30, totaling $616,250; no other company-specific developments are provided.

02

Market read

Primarily a sentiment/positioning datapoint from insider activity; not a fundamental catalyst.

03

What to watch

No 10b5-1 plan is indicated, but the filing doesn’t clarify intent; traders should watch for follow-on insider buys/sales or other contemporaneous corporate actions.

Relevance 5/10Novelty 5/10Timing: new Form 4 filed 2026-07-02 (after-hours/late day)

Background

The filing is an SEC Form 4 insider transaction for KEWAUNEE SCIENTIFIC CORP /DE/ (KEQU).

Company-level read

Ticker impact

$KEQUNeutralMedium confidence
Context

KEQU CEO/President sold 17,000 shares to the issuer at $36.25 on 2026-06-30, disclosing $616,250 in insider selling activity.

Expected impact

Low likelihood of a sustained price move; any impact would be short-lived unless followed by additional disclosures.

Evidence & confidence

Form 4 is a primary filing and the transaction is specific, but the article provides no new fundamentals, guidance, or enforcement/contract catalyst—only an insider sale to issuer.

Market effects

No sector read-across; this is company-specific insider transaction disclosure.

None indicated.

None indicated.

Counterpoint

Because the sale is coded as “to issuer” (often buyback participation), it may be mechanical rather than a bearish signal.

Key entities

  • KEWAUNEE SCIENTIFIC CORP /DE/

    Subject of the Form 4 insider transaction; ticker KEQU.

  • HULL THOMAS DAVID III

    President & CEO; sold shares to the issuer per the Form 4.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$KEQUMed

Kewanee Scientific To Buy Nycom

Kewaunee Scientific (KEQU) agreed to acquire Nycom, the largest U.S. laboratory dealer. The deal aims to combine Nycom's expertise with Kewaunee's manufacturing for integrated solutions. KEQU shares traded down 1.19% at $32.61.

$KEQUMed

Kewaunee Scientific Announces Agreement to Acquire Nycom, Inc.

Kewaunee Scientific (KEQU) agreed to acquire Nycom, a major lab dealer, for $55M, with $20M in notes, $5M in stock, and the rest in cash. The deal aims to combine Nycom's project expertise with Kewaunee's manufacturing, enhancing lab solutions. Nycom's leadership will join Kewaunee's board and management. The transaction is expected to close in Q4 2027, pending approvals.

$KEQUMed

Kewaunee Scientific Reports Results for First Quarter of Fiscal Year 2027

KEWAUNEE SCIENTIFIC CORP /DE/ (KEQU) filed an SEC Form 8-K — Results of Operations and Financial Condition. Kewaunee Scientific Reports Results for First Quarter of Fiscal Year 2027 Exchange: NASDAQ (KEQU) Contact: Donald T. Gardner III 704/871-3274 STATESVILLE, N.C. September 9, 2026 – PRNewswire / Kewaunee Scientific Corporation (NASDAQ: KEQU) today announced results for its first qu

$KEQUMed

Kewaunee Scientific Reports Results for Fiscal Year and Fourth Quarter

KEWAUNEE SCIENTIFIC CORP /DE/ (KEQU) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 prfy26q4earningsrelease.htm EX-99.1 Document Kewaunee Scientific Reports Results for Fiscal Year and Fourth Quarter Exchange: NASDAQ (KEQU) Contact: Donald T. Gardner III 704/871-3274 STATESVILLE, N.C. June 23, 2026 – PRNewswire / Kewaunee Scientific Corporation (NASDAQ